KBIO COMPANY Inc. Logo

KBIO COMPANY Inc.

Using a plant-based platform to rapidly develop biologics for public health.

038530 | KO

Overview

Corporate Details

ISIN(s):
KR7038530002
LEI:
Country:
South Korea
Address:
서울특별시 강동구 올림픽로 834 206호(암사동, 한강시티라이프), 강동구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

KBio is a biotechnology company that develops and manufactures biologics using its proprietary plant-based platform, RP3. The company leverages plants as efficient biofoundries to produce high-quality proteins, therapeutics, and bioactive compounds at scale. This innovative and sustainable approach is designed to accelerate research, development, and production timelines, surpassing the limitations of traditional manufacturing methods. KBio's platform aims to address public health challenges by enabling the rapid, large-scale production of novel biomolecules and treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.0 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.7 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 486.5 KB
2025-03-11 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.8 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.1 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 181.2 KB
2025-03-07 00:00
Share Issue/Capital Change
감자결정(종속회사의주요경영사항)
Korean 15.6 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.3 MB
2024-10-18 00:00
Capital/Financing Update
기타경영사항(자율공시) (자기사채(제26회차 전환사채) 소각 결정의 건)
Korean 5.0 KB
2024-08-14 00:00
Interim Report
반기보고서 (2024.06)
Korean 1.4 MB
2024-06-14 00:00
Regulatory News Service
본점소재지변경
Korean 5.0 KB

Automate Your Workflow. Get a real-time feed of all KBIO COMPANY Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KBIO COMPANY Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KBIO COMPANY Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemical Works of Gedeon Richter Plc Logo
Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.
Hungary
RICHT
Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR

Talk to a Data Expert

Have a question? We'll get back to you promptly.